Raven is a women-focused telehealth platform operating in Canada that provides access to GLP-1 receptor agonist medications including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and related agents for weight management. The platform operates through remote consultation models designed to streamline patient access to pharmacotherapeutic options for obesity and weight loss. As a specialized telehealth service restricting enrollment to female patients, Raven represents a segment of the emerging direct-to-consumer GLP-1 distribution landscape that has expanded significantly across North American markets since 2023.
The clinical relevance of women-focused GLP-1 telehealth services centers on several practical considerations for prescribers managing patients who may utilize or inquire about such platforms. These services typically bypass traditional primary care gatekeeping and enable rapid initiation of pharmacotherapy, which creates both opportunities for timely intervention in appropriate candidates and risks of inadequate baseline metabolic assessment or contraindication screening. Prescribers should be aware that patients accessing GLP-1s through specialized telehealth channels may lack comprehensive metabolic evaluation, medication interaction review, or baseline renal and thyroid assessment that standard clinical practice would include. Additionally, the exclusive female enrollment model may reflect marketing strategy rather than pharmacological difference, though pregnancy prevention counseling and menstrual cycle considerations become particularly relevant in this demographic.
For prescribers encountering patients already initiated on GLP-1 therapy through such platforms, the clinical imperative involves establishing continuity through baseline laboratory assessment, cardiovascular risk stratification, diabetes screening, and renal function evaluation if not previously completed. Dose escalation protocols, medication switching decisions, and long-term monitoring for pancreatitis, gallbladder disease, retinopathy changes in diabetic patients, and medullary thyroid carcinoma risk require physician-level oversight regardless of prescription origin. Coordination of care between telehealth providers and primary care physicians remains essential for comprehensive metabolic management and risk mitigation.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is Raven and what medications do they prescribe?
- Is Raven available for men or only for women?
- How do I know if I am a good candidate for GLP-1 therapy?
- What is the difference between Ozempic, Wegovy, Mounjaro, and Zepbound?
- How much does GLP-1 treatment cost through Raven?
- Will my provincial health insurance cover GLP-1 medications from Raven?
- What is the process for getting started with Raven?
- Are there side effects I should expect from GLP-1 medications?
- How long does it take to see weight loss results with GLP-1 therapy?
- What happens if I stop taking GLP-1 medication?
FAQ
What is Raven and what medications do they prescribe?
Raven is a women-only telehealth clinic operating in Canada that specializes in prescribing GLP-1 medications for weight loss, including Ozempic, Wegovy, Mounjaro, and Zepbound. These are prescription medications that help reduce appetite and support weight management when combined with lifestyle changes.
Is Raven available for men or only for women?
Raven is exclusively a women-only clinic, so men cannot access their services. If you are a man seeking GLP-1 therapy, you will need to consult with your family physician or find an alternative telehealth provider that serves male patients.
How do I know if I am a good candidate for GLP-1 therapy?
A good candidate typically has a BMI over 27 with weight-related health conditions or a BMI over 30, though your prescribing physician will assess your individual medical history, current medications, and health goals. GLP-1 medications work best when combined with dietary changes and regular physical activity.
What is the difference between Ozempic, Wegovy, Mounjaro, and Zepbound?
While all are GLP-1 or GLP-1 receptor agonist medications that help with weight loss, they differ in their active ingredients, dosing schedules, and how they work in your body. Your physician will determine which medication is most appropriate based on your medical history and specific needs.
How much does GLP-1 treatment cost through Raven?
Pricing varies depending on which medication is prescribed, dosage requirements, and whether your provincial health plan or private insurance provides coverage. You should contact Raven directly for specific pricing information and to understand what your insurance may cover.
Will my provincial health insurance cover GLP-1 medications from Raven?
Coverage varies significantly across Canadian provinces and individual insurance plans. Some provinces cover these medications for certain medical indications, while others may not, so you should verify coverage with your specific provincial health plan before starting treatment.
What is the process for getting started with Raven?
The typical process involves an initial consultation with a Raven physician via telehealth, where they review your medical history and health goals. If approved, you will receive a prescription and ongoing guidance, though the exact process details should be confirmed directly with Raven.
Are there side effects I should expect from GLP-1 medications?
Common side effects include nausea, vomiting, constipation, and diarrhea, particularly when starting or increasing doses. Most side effects are temporary and tend to improve over time, but you should report any concerning symptoms to your prescribing physician.
How long does it take to see weight loss results with GLP-1 therapy?
Most patients begin experiencing noticeable appetite reduction within the first few weeks, with measurable weight loss typically occurring within one to three months. Individual results vary based on dose, adherence to treatment, diet quality, and physical activity levels.
What happens if I stop taking GLP-1 medication?
When you discontinue GLP-1 therapy, appetite typically returns and weight regain is possible if diet and exercise habits do not support weight maintenance. Long-term weight management success requires sustained lifestyle changes regardless of whether you continue medication.
